智翔金泰(688443.SH)：2025年预亏4.81亿元至5.87亿元

Core Viewpoint - The company expects a significant reduction in net losses for the fiscal year 2025, indicating improved financial performance compared to the previous year [1] Financial Performance - The projected net profit attributable to the parent company for 2025 is expected to be between -480.64 million and -587.45 million yuan, representing a decrease in losses by 209.83 million to 316.64 million yuan, or a year-on-year reduction of 26.32% to 39.71% [1] - The expected net profit attributable to the parent company after deducting non-recurring gains and losses is projected to be between -523.63 million and -630.44 million yuan, with a decrease in losses by 173.89 million to 280.70 million yuan, translating to a year-on-year reduction of 21.62% to 34.90% [1] Research and Development - The company is committed to innovation at the source and is efficiently advancing the progress of various research projects [1] - Several products are entering clinical research phases, and core products are entering critical clinical trial stages, maintaining a high level of R&D investment [1] - The company will not incur share-based payment expenses in 2025, as the equity incentive plan for the core team implemented in 2022 will expire in 2024, leading to a reduction in corresponding expenses during the reporting period [1]